Merck
MSD’s antiviral drug hits endpoint targets in Phase III trials
October 20, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AiCuris, MSD, Merck, bone marrow, letermovir, transplant
MSD, known as Merck in the US, released news of the successful meeting of its primary endpoints in its Phase …
Apitope reclaims multiple sclerosis treatment from Merck after 7 years
October 17, 2016Sales and Marketing ATX-MS-1467, Apitope, Merck, multiple sclerosis
Apitope has announced it has reclaimed the global rights to its multiple sclerosis (MS) treatment ATX-MS-1467 from Merck for the …
MSD’s Keytruda twice as successful against standard therapy for lung cancer
October 10, 2016Sales and Marketing Bristol-Myers Squibb, MSD, Merck, keytruda
MSD, known as Merck in North America, released data that displayed the success of their drug, Keytruda, in a 123-patient …
Merck’s Keytruda suffers rejection at hands of NICE
October 5, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing MSD, Merck, NHS, NICE, keytruda
NICE rejected Merck’s Keytruda, a treatment for advanced non-small-cell lung cancer (NSCLC), on the basis that the drug was not …
Merck elects Isabel De Paoli as CSO
September 27, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CSO, Merck, appointment
German pharma firm Merck has appointed Isabel De Paoli to the position of chief science officer in addition to her …
Merck elects Isabel De Paoli as CSO
September 26, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Merck, appointment
German pharma firm Merck has appointed Isabel De Paoli to the position of chief science officer in addition to her …
Roche’s Ocrevus more effective than Merck’s Rebif, company claims
September 14, 2016Research and Development Merck, Ocrevus, Rebif, Roche, multiple sclerosis
Roche has announced new results from the Phase III studies of investigational medicine Ocrevus (ocrelizumab) studying relapsing multiple sclerosis (RMS) …
FDA to review MSD’s Keytruda as a first-line lung cancer treatment
September 7, 2016Research and Development FDA, MSD, Merck, first-line, keytruda, lung cancer, non-small cell lung cancer, opdivo
The US Food and Drug Administration has accepted the supplemental biologics license application from MSD, known as Merck in the …
MSD drops osteoporosis trial drug due to stroke risk
September 5, 2016Research and Development, Sales and Marketing MSD, Merck, Odanacatib, osteoporosis, stroke
MSD, known as Merck in the US and Canada, has announced that it has finally decided to discontinue the development …
MSD joins Medivation race, says reports
August 18, 2016Manufacturing and Production, Research and Development, Sales and Marketing MSD, Medivation, Merck, Pfizer, Sanofi, Xtandi, takeover
MSD, known as Merck in the US and Canada, is said to have declared its interest in buying US oncology …
Merck Q2 results beat analyst estimates
August 4, 2016Medical Communications, Sales and Marketing Merck, financial results
Germany pharmaceutical firm Merck has announced its fiscal results for Q2 2016, beating analyst estimates with earnings before interest, taxes, …
MSD scores EU approval for Keytruda in lung cancer
August 3, 2016Research and Development, Sales and Marketing EU, MSD, Merck, approval, keytruda, lung cancer
MSD, called Merck in the US and Canada, has announced that the European Commission has approved Keytruda (pembrolizumab) for patients …
400 current and former employees join sexual discrimination lawsuit against MSD
July 25, 2016Research and Development, Sales and Marketing MSD, Merck, discrimination, lawsuit
Over 400 women have come forward to join a $250 million gender bias class action against MSD, called Merck in …
MSD faces delay in C. diff drug approval as FDA requests more data
July 22, 2016Medical Communications, Research and Development C diff, FDA, MSD, Merck
MSD, known as Merck in the US and Canada, has received a setback in its bid to get new C. …
UK medical charity sells part of interest in MSD’s Keytruda for $150 million
July 15, 2016Research and Development, Sales and Marketing MSD, Merck, keytruda
UK medical research charity MRC Technology sold part of its royalty interest in US pharma major MSD’s (NYSE: MRK) immunotherapy …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
